•Psoriasis (PsO) is an immune mediated chronic inflammatory disease with severe disease burden associated with several comorbidities and impact on quality of life. Psoriatic arthritis (PsA) is a spondyloarthritic condition, which is present in up to 42% of individuals with psoriasis. •Studies have shown that patients with psoriasis, PsA or both generally have poorer quality of life outcomes, work productivity and functionality similar to other serious diseases such as heart disease and diabetes. •The objective of this study is to characterize the PsO patients with psoriatic arthritis (PsA) and examine association of outcomes with PsAin the Corrona Psoriasis Registry, a large prospective registry that was launched in collaboration with the National Psoriasis Foundation (NPF) to study the comparative effectiveness, safety of approved systemic PsO therapies and treatment patterns in a real world setting.
Comorbidity Burden and Characterization of Psoriasis (PsO) Patients with Concurrent Psoriatic Arthritis (PsA) in the Corrona Psoriasis Registry
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry
•Psoriasis (PsO) is an immune mediated chronic inflammatory disease, which has significant impact on health related quality of life (HRQoL). Disease severity and assessment of patient reported outcomes (PROs) has become increasingly important for defining effective treatment options. •The objective of this study is to examine the association between disease severity measured by Psoriasis Area and Severity Index (PASI) and patient reported outcomes (PROs) at enrollment in the Corrona Psoriasis Registry, a prospective observational cohort of PsO patients.